BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 24551200)

  • 1. Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancer.
    Shao C; Liao CP; Hu P; Chu CY; Zhang L; Bui MH; Ng CS; Josephson DY; Knudsen B; Tighiouart M; Kim HL; Zhau HE; Chung LW; Wang R; Posadas EM
    PLoS One; 2014; 9(2):e88967. PubMed ID: 24551200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
    Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
    Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analogous detection of circulating tumor cells using the AccuCyte
    van der Toom EE; Groot VP; Glavaris SA; Gemenetzis G; Chalfin HJ; Wood LD; Wolfgang CL; de la Rosette JJMCH; de Reijke TM; Pienta KJ
    Prostate; 2018 Mar; 78(4):300-307. PubMed ID: 29285777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of size-based separation and selection-free technology provides higher circulating tumour cells detection sensitivity than either method alone in patients with metastatic prostate cancer.
    Dong L; Zhang Z; Smith K; Kuczler MD; Reyes D; Amend SR; Cho YK; Xue W; Pienta KJ
    BJU Int; 2020 Jul; 126(1):191-201. PubMed ID: 32115854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
    Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
    Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial.
    Mandel PC; Huland H; Tiebel A; Haese A; Salomon G; Budäus L; Tilki D; Chun F; Heinzer H; Graefen M; Pantel K; Riethdorf S; Steuber T
    Eur Urol Focus; 2021 Jan; 7(1):55-62. PubMed ID: 31178293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NanoVelcro Chip for CTC enumeration in prostate cancer patients.
    Lu YT; Zhao L; Shen Q; Garcia MA; Wu D; Hou S; Song M; Xu X; Ouyang WH; Ouyang WW; Lichterman J; Luo Z; Xuan X; Huang J; Chung LW; Rettig M; Tseng HR; Shao C; Posadas EM
    Methods; 2013 Dec; 64(2):144-52. PubMed ID: 23816790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases.
    Chen JF; Ho H; Lichterman J; Lu YT; Zhang Y; Garcia MA; Chen SF; Liang AJ; Hodara E; Zhau HE; Hou S; Ahmed RS; Luthringer DJ; Huang J; Li KC; Chung LW; Ke Z; Tseng HR; Posadas EM
    Cancer; 2015 Sep; 121(18):3240-51. PubMed ID: 25975562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study.
    Theil G; Fischer K; Weber E; Medek R; Hoda R; Lücke K; Fornara P
    PLoS One; 2016; 11(8):e0158354. PubMed ID: 27479125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acoustic Enrichment of Heterogeneous Circulating Tumor Cells and Clusters from Metastatic Prostate Cancer Patients.
    Magnusson C; Augustsson P; Undvall Anand E; Lenshof A; Josefsson A; Welén K; Bjartell A; Ceder Y; Lilja H; Laurell T
    Anal Chem; 2024 May; 96(18):6914-6921. PubMed ID: 38655666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy.
    Lowes LE; Lock M; Rodrigues G; D'Souza D; Bauman G; Ahmad B; Venkatesan V; Allan AL; Sexton T
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):358-64. PubMed ID: 26238233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study.
    Zapatero A; Gómez-Caamaño A; Cabeza Rodriguez MÁ; Muinelo-Romay L; Martin de Vidales C; Abalo A; Calvo Crespo P; Leon Mateos L; Olivier C; Vega Piris LV
    Radiat Oncol; 2020 Jun; 15(1):137. PubMed ID: 32487218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells.
    Mout L; van Dessel LF; Kraan J; de Jong AC; Neves RPL; Erkens-Schulze S; Beaufort CM; Sieuwerts AM; van Riet J; Woo TLC; de Wit R; Sleijfer S; Hamberg P; Sandberg Y; Te Boekhorst PAW; van de Werken HJG; Martens JWM; Stoecklein NH; van Weerden WM; Lolkema MP
    Eur J Cancer; 2021 Jun; 150():179-189. PubMed ID: 33932725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
    Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK
    Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application.
    Chen F; Wang S; Fang Y; Zheng L; Zhi X; Cheng B; Chen Y; Zhang C; Shi D; Song H; Cai C; Zhou P; Xiong B
    Oncotarget; 2017 Jan; 8(2):3029-3041. PubMed ID: 27935872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microfluidic enrichment of circulating tumor cells in patients with clinically localized prostate cancer.
    Todenhöfer T; Park ES; Duffy S; Deng X; Jin C; Abdi H; Ma H; Black PC
    Urol Oncol; 2016 Nov; 34(11):483.e9-483.e16. PubMed ID: 27658563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status.
    Moreno JG; O'Hara SM; Gross S; Doyle G; Fritsche H; Gomella LG; Terstappen LW
    Urology; 2001 Sep; 58(3):386-92. PubMed ID: 11549486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor cells in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score.
    Kolostova K; Broul M; Schraml J; Cegan M; Matkowski R; Fiutowski M; Bobek V
    Anticancer Res; 2014 Jul; 34(7):3641-6. PubMed ID: 24982381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
    Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
    Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation of rare circulating tumour cells in cancer patients by microchip technology.
    Nagrath S; Sequist LV; Maheswaran S; Bell DW; Irimia D; Ulkus L; Smith MR; Kwak EL; Digumarthy S; Muzikansky A; Ryan P; Balis UJ; Tompkins RG; Haber DA; Toner M
    Nature; 2007 Dec; 450(7173):1235-9. PubMed ID: 18097410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.